Search clinical trials for: Florbetaben (BAY94-9172)

Total 184 results

Life Molecular Imaging SA

Completed

Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers

Alzheimer Disease | Amyloid Beta-Protein

United States, Switzerland, Australia, Germany, Japan
Life Molecular Imaging SA

Completed

Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology

Alzheimer Disease

United States, France, Japan, Australia, Germany
Life Molecular Imaging SA

Completed

Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients

Alzheimer Disease | Amyloid Beta-Protein

Australia
Life Molecular Imaging SA

Completed

Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.

Down Syndrome | Amyloid Beta-protein

United States
New York State Psychiatric Institute
Bayer; National Institute on Aging (NIA)

Completed

Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172

Late Onset Alzheimer Disease

United States
Bayer

Completed

Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

Hemophilia A

United States
Columbia University
National Institute on Aging (NIA)

Recruiting

Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease

Alzheimer Disease

United States
Bayer

Completed

Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets

Heart Failure

Germany
Judit Pich Martínez

Terminated

Study of Genetic Alzheimer's Disease Mutation Carriers in Preclinical Stages of the Disease 18F-Florbetaben Positron Emission Tomography Study

Alzheimer Disease

Spain
IRCCS Policlinico S. Matteo

Recruiting

Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis

AL Amyloidosis

Italy
Adam Brickman
National Institute on Aging (NIA)

Completed

Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults

Alzheimer Disease

United States
National Institute on Alcohol Abuse and Alcoholism...

Completed

Brain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy People

Normal Physiology

United States
Sinotau Pharmaceutical Group

Completed

A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population

Mental Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Neurocognitive Disorders | Neurodegenerative Diseases | Dementia | Alzheimer Disease | Tauopathies

China
Life Molecular Imaging GmbH
pharmtrace klinische Entwicklung GmbH

Recruiting

Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis (CArdiag)

AL Amyloidosis | Cardiac Amyloidosis | ATTR Amyloidosis

United States, Spain, Germany, United Kingdom
Fundacion Clinic per a la Recerca Biomédica

Unknown

Subjects With Subjective Cognitive Decline: 18F-Florbetaben Positron Emission Tomography Study

Subjective Cognitive Decline
Yaakov Stern
National Institute on Aging (NIA)

Completed

Imaging of Cognition, Learning, and Memory in Aging

Alzheimer's Disease

United States
Central Hospital, Nancy, France

Completed

18F-Florbetaben PET Amyloid Imaging in Case of Intermediate CSF Biology for the Diagnosis of Alzheimer's Disease : a Pilot Study (MAF)

Amyloid PET Imaging

France
Ulsan University Hospital

Completed

Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission Tomography (PET)

Multiple Myeloma

Korea, Republic of
Life Molecular Imaging SA

Completed

Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation

Neoplasms | Diagnostic Imaging

Korea, Republic of, United States, Germany
Bayer

Completed

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects

Pharmacokinetics

Germany
Bayer

Completed

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR) (ReFineDR)

Diabetic Retinopathy

Korea, Republic of, Russian Federation, Hong Kong, Taiwan, United States, Argentina, Japan, Denmark, Israel, Spain, Sweden, China, Colombia, Italy, Portugal
Columbia University
National Institute on Aging (NIA)

Completed

Brain Vascular Disease in Aging and Dementia

Dementia | Alzheimer Disease | Aging | White Matter Hyperintensities

United States
Dartmouth-Hitchcock Medical Center

Completed

Neuraceq™ PET for Detection of Brain Changes in Young Athletes Post-concussion

Concussion, Brain

United States
Alkermes, Inc.

Completed

A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

Schizophrenia

United States, Bulgaria, Korea, Republic of, Malaysia, Philippines, Romania, Russian Federation, Ukraine
James M Noble, MD, MS, CPH, FAAN
National Institute on Aging (NIA)

Recruiting

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease (ADVISe)

Alzheimer Disease

United States
Bayer

Completed

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN)

Diabetic Nephropathies

Hong Kong, Australia, Spain, Portugal, United States, France, Canada, Netherlands, Austria, Finland, Poland, Taiwan, Hungary, Israel, Italy, South Africa, Sweden, Bulgaria, Germany, Denmark, Czechia, Korea, Republic of, Norway
Bayer

Completed

A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution

Chronic Kidney Disease | Worsening Chronic Heart Failure

Germany
Bayer

Active, not recruiting

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (FIND-CKD)

Non-diabetic Chronic Kidney Disease

Hong Kong, United States, Spain, China, Belgium, Taiwan, Australia, Korea, Republic of, Russian Federation, United Kingdom, Singapore, Malaysia, Japan, Greece, Israel, Hungary, Italy, Czechia, Denmark, Argentina, Bulgaria, Mexico, I... and more
Life Molecular Imaging SA

Completed

Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer

Neoplasms

United States
Columbia University

Completed

Imaging Inflammation in Alzheimer's Disease With 11C-ER176

Alzheimer Disease

United States
Northwestern University

Completed

Florbetaben PET Imaging in PPA

Alzheimer Disease | Primary Progressive Aphasia

United States
Stanford University

Completed

PET/MRI Evaluation of Cardiac Amyloid

Cardiac Amyloidosis

United States
Bayer

Completed

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers

Pharmacokinetics

Germany
Alkermes, Inc.

Completed

A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia

Schizophrenia

United States
Istituti Clinici Scientifici Maugeri SpA

Recruiting

Demyelination and Remyelination in Multiple Sclerosis (MS) Detected by Brain Amyloid PET-CT

Multiple Sclerosis

Italy
Bayer

Recruiting

A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus | Chronic Kidney Disease

India
Bayer

Recruiting

A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting

Type 2 Diabetes Mellitus | Chronic Kidney Disease

United States, Germany, Argentina, Belgium, Brazil, Canada, Chile, Colombia, France, Italy, Korea, Republic of, Luxembourg, Mexico, Netherlands, Russian Federation, Saudi Arabia, Singapore, Slovenia, Spain, Switzerland, Taiwan, Th... and more
Bayer

Completed

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease (FIDELIO-DKD)

Chronic Kidney Disease

Belgium, Finland, France, China, Hong Kong, Switzerland, United States, Turkey, Greece, New Zealand, Poland, South Africa, Spain, Korea, Republic of, Portugal, Taiwan, Japan, Russian Federation, Singapore, Australia, Netherlands, ... and more
Bayer

Completed

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR) (DeFineDR)

Diabetic Retinopathy

United Kingdom, Bulgaria
Bayer

Completed

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease (FIGARO-DKD)

Diabetic Kidney Disease

Belgium, Finland, France, Spain, China, Hong Kong, Switzerland, United States, Colombia, Turkey, Greece, New Zealand, Poland, Korea, Republic of, Portugal, Taiwan, Japan, Russian Federation, Singapore, Australia, Netherlands, Sweden, Austr... and more
Bayer

Completed

Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.

Oncology

United States
Bayer

Completed

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)

Diabetic Nephropathies

Japan
Alkermes, Inc.

Completed

An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

Schizophrenia

United States, Bulgaria, Korea, Republic of, Malaysia, Philippines, Romania, Russian Federation, Ukraine
Bayer

Completed

Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies

Neoplasms

Japan
Bayer

Completed

An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants (FIGARO-BM)

Type 2 Diabetes Mellitus | Chronic Kidney Disease

Spain, Belgium, United States, Russian Federation, Hong Kong, Singapore, Taiwan, Korea, Republic of, Canada, Austria, Italy, Japan, Denmark, Australia, Bulgaria, Czechia, Finland, Israel, Netherlands, Sweden, Portugal
Fondazione Toscana Gabriele Monasterio

Recruiting

18F-florbetaben PET-CT to Non-invasively Diagnose Cardiac AL Amyloidosis (PETAL)

Amyloid | Amyloid Cardiomyopathy

Italy
Ironwood Pharmaceuticals, Inc.

Terminated

Phase 2a Study of IW-9179 to Treat Functional Dyspepsia

Dyspepsia | Functional Gastrointestinal Disorders

Belgium, Netherlands
Merck Sharp & Dohme LLC

Terminated

Study of MK-1972 in Human Immunodeficiency Virus (HIV)-1 Infected Participants Who Have Not Previously Received Antiretroviral Therapy (MK-1972-003)

HIV-1 Infection
Taisho Pharmaceutical Co., Ltd.

Completed

A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Hyperphosphatemia Patients on Hemodialysis

Japan
Bayer

Recruiting

A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus Patients (SMART-Finder)

Type 2 Diabetes Mellitus | Chronic Kidney Disease

Germany

Search clinical trials for: Florbetaben (BAY94-9172)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations